+A -A

Tabela:
Comparative View:

1Q19 Create chart
Net sales revenues 1,072,534
Change in Fair Value of Biological Assets 19,173
Cost of Goods Sold -656,520
Depreciation / Amortization / exhaustion -115,240
Exhaustion of biological assets -38,487
Gross Profit 281,460
Selling Expenses -161,709
General and Administrative Expenses -46,643
Management Compensation -3,992
Other Operating Compensation -6,156
Equity income from subsidiaries null
Operating Profit before Financial Income and Equity 62,960
Financial Income 25,286
Financial Expenses -53,812
Income Before Income Tax and Social Contribution 34,434
Income and social contribution taxes - current -18,463
Income Tax and Social Contribution - Deferred 7,927
Effect profit from discontinued operation 0
Net Income 23,898
Recurring Net Income 19,262
Recurring EBITDA 179,307
EBITDA Margin 17.1 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza